To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy.
To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy.
-  Study population:Person with HBeAg negative CHB on TDF/ETV for more than 1 year

 -  Study design:Prospective,Interventional (single arm study)

 -  Sample size: All the patients fulfilling the inclusion criteria will be included in
 first 6 months and subsequently followed up for 2 years

 -  Intervention: Peg IFN 2b 1.5mcg/kg once every week for 48 weeks

 -  Monitoring and assessment: LFT,HBV DNA and HbsAg at baseline, 4 weeks, 12 weeks,24
 weeks,48 weeks ,72 weeks and 96 weeks, CBC every month and Thyroid function Test every
 3rd month

 -  Adverse effects: The most frequently reported side effects of IFN-based therapy are
 flu-like symptoms, headache, fatigue, myalgia, alopecia, and local reaction at the
 injection site. Peg-IFN have myelosuppressive effects; however, neutropenia\1000/mm3 and
 thrombocytopenia \500,000/ mm3 are not common unless patients already have cirrhosis
Inclusion Criteria:

 - HBeAg negative Chronic HBV infection who are having HBV DNA-undetectable. ALT <40 IU/ml
 No Advanced fibrosis[LSM <14 KPa] TDF/ETV >1 year Clinical Relapse after stopping NA will
 be defined as HBV DNA>2000IU/ml and ALT > 80IU

 Exclusion Criteria:

 - HBeAg+ CHB Pregnancy Cirrhosis on biopsy or LSM >14 Co-infection- HIV/HCV/HDV
 Immunosuppressive therapy Renal failure S.Bilirubin>2mg/dl Patient having neutropenia